HLA-C and cancer: Besides the three immune subset ratios that were used to select virtual patients in the present analysis (Fig. 2), there are other patient characteristics, such as cancer cell growth rate, T cell clonality, and binding affinity between neoantigen and MHC molecules, which also differ among patients but cannot be directly obtained from the immunogenomic data.